Our response to the NICE Early Value Assessment:
Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway
Skin cancer generates the most urgent referrals of any cancer in the UK and referrals are growing by over 10% year on year [1]. At the same time, 1 in 4 Consultant Dermatologist posts remain unfilled [2]. Despite sustained and considerable effort from dermatology departments, this has led to waitlists growing significantly. In 2024 >100,000 patients waited more than 28 days after urgent cancer referral for their diagnosis [1], while NHS data suggests that as of September 2024, around 450,000 patients are waiting on Referral to Treatment pathways, with 39% of dermatology patients waiting more than 18 weeks. [3]
Skin Analytics’ UKCA marked Class IIa and Class III CE marked AI as a Medical Device (AIaMD), DERM (Deep Ensemble for the Recognition of Malignancy), is built around our custom built teledermatology platform to help triage patients into the right place, at the right time and to conserve dermatologist capacity for patients who need it.
DERM safely triages patients with non-cancerous lesions away from cancer pathways, allowing dermatologists to focus on the patients that need them most.
Skin Analytics deploys the first and only use of autonomous AI for dermatology in the NHS
Our latest quarterly report showed
appropriate ruling out of skin cancer and
benign lesion biopsies can be prevented
In NHS Primary Care, DERM typically avoids urgent suspected cancer referrals for up to
of patients with 40-55% discharged
Skin Analytics has helped Secondary Care organisations avoid up to
of NHS face-to-face USCRs by combining DERM with downstream teledermatology reviews where patients can be routed straight to biopsy
Skin Analytics has 22 deployments using DERM across the NHS
If you would like to know more about how Skin Analytics can help you and your dermatology team deliver best in class dermatology, get in touch.
